statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Champions Oncology ( NASDAQ:CSBR ) Third Quarter 2024 Results Key Financial Results Revenue: US$12.0m (down 5.9% from...

Champions Oncology Third Quarter 2024 Earnings: US$0.19 loss per share (vs US$0.18 loss in 3Q 2023)

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Craig-Hallum gets more bearish on Champions Oncology, downgrades shares

Champions Oncology, Inc. (CSBR) Q3 2024 Earnings Call Transcript...

Champions Oncology, Inc. (CSBR) Q3 2024 Earnings Call Transcript

Champions Oncology Non-GAAP EPS of -$0.16, revenue of $12M...

Champions Oncology Non-GAAP EPS of -$0.16, revenue of $12M

Champions Oncology: Q3 Earnings Insights

HACKENSACK, NJ / ACCESSWIRE / March 12, 2024 / Champions Oncology, Inc. (NASDAQ:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, today...

Champions Oncology Reports Quarterly Revenue of $12.0 Million

Champions Oncology (NASDAQ:CSBR) publica su pr xima ronda de ganancias este martes, 12 de marzo. Esta es la gu a esencial de Benzinga para el informe de ganancias del tercer trimestre de Champions...

Avance: ganancias de Champions Oncology

Champions Oncology (NASDAQ:CSBR) pubblicher i prossimi risultati degli utili questo marted 12 marzo. Per tutte le informazioni in merito, ecco la tua guida sulla pubblicazione degli utili di marted...

Anteprima degli utili: Champions Oncology

Craig-Hallum analyst Matt Hewitt assigned a Buy rating to the stock today. The company's shares closed yesterday at $5.61. According to TipRanks, H...

Craig-Hallum Gives a Buy Rating to Champions Oncology (CSBR)

HACKENSACK, NJ / ACCESSWIRE / March 7, 2024 / Champions Oncology, Inc. (NASDAQ:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, announced...

Champions Oncology's US Laboratory has Acquired Distinguished CAP Accreditation

Champions Oncology, Inc. engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The company was founded by James M. Martell and David Sidransky on June 4, 1985 and is headquartered in Hackensack, NJ.

Volume	1,048.00
52-Wk High	$7.32
52-Wk Low	$4.17

Period	Estimated	Reported	Surprise	Result
Q4'23	-$0.16	--	--	N/A
Q3'23	-$0.06	-$0.16	-166.67%	MISSED
Q2'23	-$0.16	-$0.15	8.16%	BEAT
Q1'23	-$0.11	--	--	N/A
Q4'22	-$0.08	--	--	N/A

CSBR Champions Oncology Inc

About

Feed

News

Earnings

Fundamentals